-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
17 Feb 2026
-
Net transactions value
-
-$2,289,666
-
Form type
-
4
-
Filing time
-
19 Feb 2026, 16:12:47 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Bunnage Mark E. |
EVP, Chief Scientific Officer |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
19 Feb 2026 |
0002100735 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Award |
$0 |
+2,584 |
+24% |
$0.000000 |
13,215 |
17 Feb 2026 |
Direct |
F1 |
| transaction |
VRTX |
Common Stock |
Tax liability |
$536,962 |
-1,110 |
-8.4% |
$483.75 |
12,105 |
17 Feb 2026 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$1,192,814 |
-2,437 |
-20% |
$489.46 |
9,668 |
17 Feb 2026 |
Direct |
F2 |
| transaction |
VRTX |
Common Stock |
Sale |
$559,890 |
-1,182 |
-12% |
$473.68 |
8,486 |
18 Feb 2026 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: